Table 2.
Summary Measures for Each Analyte for the Unstimulated and Background-adjusted Values
| Analyte | Control | Incident TB | Prevalent TB | TB-combined |
|---|---|---|---|---|
| Unstimulated | ||||
| CCL3 | 1973.9 (1070.1, 4427.7) | 2077.9 (1111.4, 4098.6) | 2396.5 (869.0, 4133.5) | 2291.0 (969.4, 4117.9) |
| CCL4 | 1411.1 (809.9, 2280.0) | 1608.4 (959.3, 2774.7) | 1394.7 (660.8, 2186.4) | 1450.5 (735.9, 2428.5) |
| CXCL10 | 4325.9 (2593.1, 8577.5) | 5748.5 (2925.8, 8621.0) | 6717.0 (3981.0, 10413.3) | 6126.6 (3742.1, 9437.5) |
| EGF | 274.0 (178.8, 380.4) | 247.7 (148.6, 344.4) | 236.6 (169.9, 321.2) | 245.9 (164.0, 332.8) |
| IFN-α2 | 82.0 (29.0, 127.9) | 105.5 (73.3, 145.8) | 99.7 (51.3, 149.3) | 104.7 (60.7, 148.7) |
| IFN-γ | 8.6 (3.0, 15.2) | 11.8 (8.0, 16.4) | 11.5 (8.2, 23.0) | 11.7 (8.0, 21.0) |
| IL-10 | 10.2 (3.0, 23.5) | 14.0 (6.9, 27.7) | 11.3 (6.1, 21.4) | 12.5 (6.2, 25.7) |
| IL-1α | 32.3 (4.8, 83.2) | 28.5 (4.5, 59.6) | 16.6 (3.6, 48.2) | 20.6 (3.6, 56.7) |
| IL-2 | 4.0 (3.0, 6.6) | 4.7 (3.0, 6.3) | 7.7 (6.6, 8.5) | 7.1 (5.6, 8.1) |
| sCD40L | 1046.5 (490.5, 2102.6) | 889.1 (645.0, 2260.7) | 930.5 (415.7, 2915.1) | 898.0 (454.6, 2494.2) |
| TGF-α | 12.3 (7.1, 19.4) | 14.1 (8.6, 20.6) | 16.8 (12.1, 22.7) | 16.1 (10.3, 22.1) |
| TNF | 113.8 (47.5, 258.0) | 143.1 (58.7, 300.6) | 139.4 (67.1, 257.1) | 139.4 (61.4, 283.1) |
| VEGF | 379.0 (205.0, 694.0) | 205.0 (205.0, 665.8) | 456.9 (205.0, 701.5) | 369.3 (205.0, 691.4) |
| Background-adjusted, Stimulated–unstimulated | ||||
| CCL3 | -132.1 (-1197.0, 655.4) | 169.7 (-1162.3, 750.3) | 44.0 (-851.8, 704.4) | 89.2 (-1026.5, 719.1) |
| CCL4 | 145.6 (-335.3, 965.1) | 404.2 (-212.1, 940.1) | 322.4 (-23.1, 1315.7) | 351.6 (-76.2, 1124.0) |
| CXCL10 | 6144.6 (1698.8, 15576.7) | 13 327.6 (4228.4, 34 531.8) | 16 242.8 (4853.8, 31 249.0) | 14 756.5 (4570.4, 31 947.6) |
| EGF | -37.5 (-76.6, -3.0) | -41.0 (-89.5, -5.1) | -43.6 (-76.5, -15.3) | -42.6 (-82.7, -10.6) |
| IFN-α2 | 0.0 (-10.1, 15.6) | 9.1 (0.0, 24.3) | 6.3 (-2.3, 16.6) | 6.5 (0.0, 20.5) |
| IFN-γ | 11.0 (0.0, 74.0) | 27.2 (1.6, 89.3) | 53.0 (13.4, 192.7) | 44.2 (10.6, 177.6) |
| IL-10 | 0.0 (-7.5, 1.5) | -2.0 (-8.8, 3.0) | -2.3 (-8.4, 0.0) | -2.2 (-8.5, 0.0) |
| IL-1α | 1.8 (-17.6, 25.5) | 0.0 (-18.4, 13.3) | 0.0 (-15.3, 16.4) | 0.0 (-17.2, 16.0) |
| IL-2 | 14.0 (1.3, 86.3) | 26.2 (1.8, 140.4) | 33.4 (5.8, 152.8) | 33.2 (5.4, 143.9) |
| sCD40L | 152.4 (-91.3, 970.7) | 291.8 (-55.3, 724.6) | 153.4 (-78.2, 1151.1) | 170.7 (-65.1, 864.5) |
| TGF-α | 0.0 (-3.6, 2.4) | 0.0 (-3.0, 4.0) | -0.6 (-4.4, 2.6) | 0.0 (-4.1, 3.4) |
| TNF | -7.8 (-74.7, 39.3) | 0.7 (-104.2, 35.0) | -1.0 (-83.6, 49.9) | -0.2 (-92.9, 40.3) |
| VEGF | 0.0 (-227.8, 200.9) | 0.0 (-116.7, 298.3) | 0.0 (-239.0, 370.7) | 0.0 (-197.5, 341.2) |
The TB-combined group includes both the TB incident and TB prevalent groups. Values are shown as pg/ml median (IQR).
Abbreviations: CCL, chemokine (C-C motif) ligand; CXCL10, C-X-C motif chemokine 10; EGF, epidermal growth factor; IFN, interferon; IL, interleukin; IQR, interquartile range; sCD40L, soluble CD40 ligand; TB, tuberculosis; TGF-α, transforming growth factor-α; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.